Close menu




September 2nd, 2021 | 11:30 CEST

HelloFresh, TeamViewer and wallstreet:online: Up to 50% price potential

  • Investments
Photo credits: pixabay.com

Record levels wherever you look: DAX, MDAX, TechDAX. Apart from minor corrections, the past few months have been a lot of fun for stock market players overall. In particular, companies benefiting from the Corona pandemic were among the high flyers. These included vaccine manufacturers such as BioNTech and Moderna, the cooking box mail order Company HelloFresh, the software Company TeamViewer and wallstreet:online. The latter is not only a stock market portal operator but is also shaking up the online broker market with their Smartbroker. All three companies have also consolidated in the meantime - sometimes more violently, sometimes less - and are still recommended by analysts. The price targets are up to 50% above the current values.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: HELLOFRESH SE INH O.N. | DE000A161408 , TEAMVIEWER AG INH O.N. | DE000A2YN900 , WALLSTREET:ONLINE INH ON | DE000A2GS609

Table of contents:


    wallstreet:online - Share with around 40% price potential

    After convincing half-year figures, Warburg Research sees around 40% price potential for the wallstreet:online AG share. In the first six months of 2021, wallstreet:online increased its revenues by 57% to EUR 23.8 million. According to Warburg analysts, this means that the Company is continuing its strong growth trend of the past year. The growth driver was the new brokerage business with +127%. Smartbroker already had around 142,000 customers at the end of June 2021 - 62,000 more than at the beginning of the year. Assets under management even increased by 240% to EUR 6.8 billion. The high quality of Smartbroker's customers is reflected in the average assets of almost EUR 30,000 per customer, who are usually experienced traders and not first-time customers, they said. The analysts expect wallstreet:online's online broker to crack the 200,000 customer mark by the end of the year. In addition, the Group's traditional platform and marketing business also posted growth. There, sales increased by 40%.

    According to Warburg estimates, wallstreet:online will be able to significantly increase its revenues in the coming years and achieve disproportionate growth in profits. Revenues are expected to rise from EUR 54 million in the current year to around EUR 81 million by 2023. At the same time, operating profit (EBITDA) is expected to climb from EUR 6.59 million (2021) to around EUR 32.6 million. That would be an increase of almost 400%. Net income is expected to increase from EUR 4.1 million in the current year to EUR 17.9 million. These numbers put the current market capitalization of around EUR 360 million into perspective. Therefore Warburg recommends the share of wallstreet:online to the purchase and calls a price target of EUR 34. The share is currently trading at around EUR 24.

    HelloFresh: Thumbs up despite lower margin

    One of the high-flyers since the beginning of the Corona pandemic is undoubtedly HelloFresh. The cooking box shipper benefited greatly from the lockdowns and exit restrictions. But the Company should also develop positively in the future. Thus, the majority of the accompanying analysts recommend the stock as a buy. Kepler Cheuvreux has slightly raised the price target for HelloFresh from EUR 102.70 to 103.60. The analysts are relaxed about the lowered margin outlook. Because the cooking box shipper invests in the expansion of capacities thus, supply bottlenecks should be avoided, and the business should continue to grow in the future. HelloFresh had reported revenues of around EUR 1.55 billion for Q2 2021 (Q2 2020: EUR 972 million), slightly higher than analysts' average expectations. Adjusted EBITDA was also slightly above analysts' expectations of EUR 155 million in the reporting period at EUR 158 million (Q2 2020: EUR 154 million). Due to the strong growth, the revenue forecast for the full year 2021 has increased from 35% - 45% to 45% - 55%. Due to the stronger than initially planned growth in fiscal year 2021 and in order to be well prepared for fiscal year 2022 and further fiscal years, HelloFresh will accelerate the further build-up of production capacities and therefore now expects higher than initially planned fulfillment costs for fiscal year 2021. As a result, the full-year 2021 adjusted EBITDA margin guidance has been reduced from 10% - 12% to 8.25% - 10.25%. This is lower than the average analyst estimates of 11.1%.

    TeamViewer: Ronaldo switch only helps briefly

    At TeamViewer, it looked for a while as if Christiano Ronaldo's move to Manchester United would give the share new momentum. The soccer superstar had surprisingly reached an agreement with Manchester United to return. TeamViewer can therefore look forward to Ronaldo's charisma in the future as the club's shirt sponsor. Manchester United's sponsorship has previously been viewed rather critically by investors, as it was the reason for the reduction in the profit forecast in March. With the signing of the world star, the costs should at least be put into perspective somewhat. Nevertheless, the share was only able to profit briefly. After the disappointing figures of the peer group company Zoom, the Teamviewer share also went down again. Nevertheless, the major Swiss bank, UBS, recommends buying the software company's stock, citing a price target of EUR 44. That means that the price potential is over 50%. However, according to the analysts, the figures for the third quarter will be decisive for the further outlook.


    The high flyers of the past year continue to be highly rated by analysts. HelloFresh and wallstreet:online in particular, appear to have excellent prospects. TeamViewer must first regain lost confidence with solid Q3 figures.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read